Single-agent gemcitabine is currently the standard treatment for advanced pancreatic cancer. A majority of recent phase III trials have shown either marginal or no improvement in survival using gemcitabine in combination with other chemotherapeutic and novel agents. Our group recently reported that the combination of gemcitabine with erlotinib was associated with a significant prolongation of survival and improvement in progression-free survival in advanced pancreatic cancer.